SFPO and ESOP recommendations for the practical stability of anticancer drugs: an update

J Vigneron; A Astier; R Trittler; J D Hecq; M Daouphars; I Larsson; B Pourroy; F Pinguet; French Society of Hospital Pharmacists; European Society of Oncology Pharmacists

doi:10.1016/j.pharma.2013.06.002

SFPO and ESOP recommendations for the practical stability of anticancer drugs: an update

Ann Pharm Fr. 2013 Nov;71(6):376-89. doi: 10.1016/j.pharma.2013.06.002. Epub 2013 Aug 28.

Authors

J Vigneron¹, A Astier, R Trittler, J D Hecq, M Daouphars, I Larsson, B Pourroy, F Pinguet; French Society of Hospital Pharmacists; European Society of Oncology Pharmacists

Affiliation

¹ Pharmacy, university hospital, rue du Morvan, 54511 Vandœuvre, France. Electronic address: [email protected].

PMID: 24206590
DOI: 10.1016/j.pharma.2013.06.002

Abstract

The recommendations for the practical stability of anticancer drugs published in 2010 by the French Society of Hospital Pharmacists (SFPO) and the European Society of Oncology Pharmacists (ESOP) have been updated. Ten new molecules have been included (asparaginase, azacitidine, bevacizumab, clofarabine, eribuline mesylate, folinate sodium, levofolinate calcium, nelarabine, rituximab, temsirolimus).

Keywords: Anticancer drugs; Anticancéreux; Anticorps monoclonaux; Dose banding; Monoclonal antibodies; Stabilis(®); Stability; Stabilité.

Publication types

Guideline

MeSH terms

Antibodies, Monoclonal / analysis
Antibodies, Monoclonal / chemistry
Antineoplastic Agents / chemistry*
Antineoplastic Agents / standards*
Chemotherapy, Adjuvant
Drug Stability
Humans
Medical Oncology
Pharmacists
Pharmacy Service, Hospital
Societies, Pharmaceutical

Substances

Antibodies, Monoclonal
Antineoplastic Agents